A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

NCT07668752 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D Mutation
NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: GFH375
DRUG: Docetaxel

Sponsor

Genfleet Therapeutics (Shanghai) Inc.